Highly selective aza-nitrile inhibitors for cathepsin K, structural optimization and molecular modeling.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Organic and biomolecular chemistry

• Publication date

  2013-08-14

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1039/c3ob41165fPMID 23900712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Highly selective azadipeptide nitrile inhibitors for cathepsin K: design, synthesis and activity assays.

  2013cited by this paper
• Identification of new peptide amides as selective cathepsin L inhibitors: the first step towards selective irreversible inhibitors?

  2013cited by this paper
• Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey

  2012cited by this paper
• Effects of Odanacatib on Bone Mineralization Density Distribution in Thoracic Spine and Femora of Ovariectomized Adult Rhesus Monkeys: A Quantitative Backscattered Electron Imaging Study

  2012cited by this paper
• (1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.

  2012cited by this paper
• Study of the lithiated phenylacetonitrile monoanions and dianions formed according to the lithiated base used (LHMDS, LDA, or n-BuLi). 2. Alkylation and deuteriation mechanism study by vibrational and NMR spectroscopy and quantum chemistry calculations.

  2012cited by this paper
• Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys

  2011cited by this paper
• ‘Corrigendum to “The major cathepsin L secreted by the invasive juvenile Fasciola hepatica prefers proline in the S2 subsite and can cleave collagen” [Mol. Biochem. Parasitol. 176 (1) (2009) 41–47]’

  2011cited by this paper
• Structural optimization of azadipeptide nitriles strongly increases association rates and allows the development of selective cathepsin inhibitors.

  2011cited by this paper
• Osteoporosis: now and the future

  2011cited by this paper
• New cathepsin inhibitors to explore the fluorophilic properties of the S2 pocket of cathepsin B: design, synthesis, and biological evaluation.

  2011cited by this paper
• Facing the gem-dialkyl effect in enzyme inhibitor design: preparation of homocycloleucine-based azadipeptide nitriles.

  2011cited by this paper
• Peptidomimetic inhibitors of cathepsin K.

  2010cited by this paper
• New treatment targets in osteoporosis.

  2010cited by this paper
• Development of nitrile-based peptidic inhibitors of cysteine cathepsins.

  2010cited by this paper
• Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study

  2009cited by this paper
• Synthetic analogues of the proteinase inhibitor: chymostatin.

  2009cited by this paper
• Virtual Screening of Cathepsin K Inhibitors Using Docking and Pharmacophore Models

  2008cited by this paper
• Azadipeptide nitriles: highly potent and proteolytically stable inhibitors of papain-like cysteine proteases.

  2008cited by this paper
• Osteoclasts secrete non-bone derived signals that induce bone formation.

  2008cited by this paper
• A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.

  2007cited by this paper
• Design and synthesis of tetracyclic nonpeptidic biaryl nitrile inhibitors of cathepsin K.

  2006cited by this paper
• Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?

  2006cited by this paper
• Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study

  2006cited by this paper
• Design of cathepsin K inhibitors for osteoporosis.

  2005cited by this paper
• Recent developments in cathepsin K inhibitor design.

  2005cited by this paper
• Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.

  2005cited by this paper
• A structural screening approach to ketoamide-based inhibitors of cathepsin K.

  2005cited by this paper
• Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.

  2004cited by this paper
• Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications.

  2004cited by this paper
• Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitors.

  2004cited by this paper
• Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors.

  2004cited by this paper
• Exploration of the P1 SAR of aldehyde cathepsin K inhibitors.

  2004cited by this paper
• A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.

  2003cited by this paper
• Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design.

  2001cited by this paper
• Crystal structure of MHC class II‐associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S

  1999cited by this paper
• Proteases involved in MHC dass II antigen presentation

  1999cited by this paper
• Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization.

  1999cited by this paper
• Use of X-Ray Co-Crystal Structures and Molecular Modeling to Design Potent and Selective Non-Peptide Inhibitors of Cathepsin K

  1998cited by this paper
• Structure and Design of Potent and Selective Cathepsin K Inhibitors

  1997cited by this paper

• Binding mechanism of selective cathepsin K/S inhibition revealed from molecular simulations

  2023cites this paper
• A patent review on cathepsin K inhibitors to treat osteoporosis (2011 – 2021)

  2022cites this paper
• Structural analysis, simulation, and molecular docking of aza-nitrile into cathepsins to explain the high selectivity

  2020cites this paper
• Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes.

  2019cites this paper
• Cathepsin B: Active site mapping with peptidic substrates and inhibitors.

  2019cites this paper
• Advances in the discovery of cathepsin K inhibitors on bone resorption

  2018cites this paper
• Chapter 8 Specific Proteases for Osteoarthritis Diagnosis and Therapy

  2018cites this paper
• Straightforward synthesis of 2,4,6-trisubstituted 1,3,5-triazine compounds targeting cysteine cathepsins K and S.

  2016cites this paper
• Azanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity, Osteoblast-Induced Mineralization and Osteoclast-Mediated Bone Resorption

  2015cites this paper
• Specific Proteases for Osteoarthritis Diagnosis and Therapy

  2015cites this paper
• 3-Cyano-3-aza-β-amino Acid Derivatives as Inhibitors of Human Cysteine Cathepsins.

  2014cites this paper
• Small molecules regulated bone resorption and enzyme activity in osseous cells

  2014influential citation
• Crucial protein based drug targets and potential inhibitors for osteoporosis: new hope and possibilities.

  2013cites this paper